Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022

  20 February 2024

The study reveals that over half of MG-positive samples in Belgium harbor resistance-associated mutations (RAMs) to macrolides, the primary treatment for MG. This is particularly prevalent in men who have sex with men (MSM), with 45% being resistant. The presence of fluoroquinolone RAMs was around 26%. The findings suggest that testing for macrolide resistance among MSM might not be necessary in Belgium, but are crucial in other populations due to lower prevalence and emerging fluoroquinolone resistance.

Further reading: EuroSurveillance
Author(s): Irith De Baetselier et al
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed